Ali Raza
Geen lopende functies
Profiel
Ali Raza served as President & Director at Sosei Co. Ltd., Head-Clinical Sciences Department at AstraZeneca PLC, and President-AeroLEF Division at YM BioSciences, Inc. He obtained an undergraduate degree from The University of Manchester and a doctorate degree from the University of London.
Eerdere bekende functies van Ali Raza
| Bedrijven | Functie | Einde |
|---|---|---|
Sosei Co. Ltd.
 Sosei Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Sosei Group Corp., Sosei Co. Ltd. is a world-leader in GPCR medicine design and development. The company is based in Tokyo, Japan. The Japanese company obtains and maintains intellectual property rights to protect its innovations and technologies. | President | - |
| ASTRAZENECA PLC | Hoofd Techniek/Wetenschap/O&O | - |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | - |
Opleiding van Ali Raza
| The University of Manchester | Undergraduate Degree |
| University of London | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Sosei Co. Ltd.
Sosei Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Sosei Group Corp., Sosei Co. Ltd. is a world-leader in GPCR medicine design and development. The company is based in Tokyo, Japan. The Japanese company obtains and maintains intellectual property rights to protect its innovations and technologies. | Commercial Services |
